Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | CDK1 | P06493 | 1/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | CDK7 | P50613 | 1/20 | 0.59 |
| ▸ | CCNH | P51946 | 1/20 | 0.59 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27927088 | 0.84 | TP53 (0.65) | FFAR4LMNATP53KEAP1NFE2L2 | |
| SCHEMBL1631204 | 0.82 | HSD17B2 (0.71) | LMNAHSD17B2TP53MEN1KMT2A | |
| SCHEMBL3782497 | 0.81 | PTGES2 (0.64) | FFAR1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL15228509 | 0.81 | MCL1 (0.70) | FFAR1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL23200380 | 0.80 | KDM1A (0.79) | FFAR1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL29083807 | 0.80 | FFAR4 (0.55) | FFAR1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL16325550 | 0.80 | FFAR4 (0.63) | FFAR1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL12396096 | 0.80 | KEAP1 (0.55) | LMNASMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL3528690 | 0.78 | KDM1A (0.61) | FFAR1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL7571635 | 0.77 | FFAR1 (0.66) | FFAR1CDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749992-B2 | Compounds and methods for treating dislipidemia | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1670768-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2098512-A1 | Compounds and methods for treating dyslipidemia | Eli Lilly & Company (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | US | disclosed |
| CN-1863778-A | Compounds and methods for treating dyslipidemia | LILLY CO ELI (US) | 2006-11-15 | — | — | CN | disclosed |
| EP-1670768-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037796-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | APOB, CETP, PCSK9 | FFAR1 120/4885CDK1 4021/4885CCNB1 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.